Search research articles
Contact Us
Filters
Showing results (1-10 of 35) with videos related to
Page
of 4
Sort By:
Expert Opinion on Drug Safety
|
October 27, 2004
Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis
Christopher McCoy
Clinical Therapeutics
|
October 9, 2007
Darunavir: a nonpeptidic antiretroviral protease inhibitor
Christopher McCoy
Clinical Therapeutics
|
September 1, 2004
Peginterferon alfa-2a: a review of approved and investigational uses
S James Matthews, Christopher McCoy
Journal of General Internal Medicine
|
January 21, 2006
Response to "Interactions between pharmaceutical representatives and doctors in training: a thematic review"
Leana S Wen, Christopher McCoy
Clinical Therapeutics
|
May 17, 2003
Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis
Christopher McCoy, Samuel James Matthews
Clinical Therapeutics
|
May 17, 2003
Thalidomide: a review of approved and investigational uses
S James Matthews, Christopher McCoy
Clinical Practice and Cases in Emergency Medicine
|
May 22, 2025
Pyoderma Grangrenosum
Reza Aghaei, Edmund Hsu, Christopher McCoy
Pharmacotherapy
|
October 28, 2009
Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients
Todd M Pollack, Christopher McCoy, Wendy Stead
Journal of Education & Teaching in Emergency Medicine
|
July 19, 2023
A Case Report of May-Thurner Syndrome Identified on Abdominal Ultrasound
Michelle Brown, Edmund Hsu, Christopher McCoy, et al.
American Journal of Medical Quality : the Official Journal of the American College of Medical Quality
|
May 23, 2015
Delayed awareness of clinically significant test results on hospital services without an automated alert system
Ruth Bates, Andrew Rosenbaum, Christopher McCoy, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 35) with videos related to
Sort By:
Page
of 4
Expert Opinion on Drug Safety
|
October 27, 2004
Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis
Christopher McCoy
Clinical Therapeutics
|
October 9, 2007
Darunavir: a nonpeptidic antiretroviral protease inhibitor
Christopher McCoy
Clinical Therapeutics
|
September 1, 2004
Peginterferon alfa-2a: a review of approved and investigational uses
S James Matthews, Christopher McCoy
Journal of General Internal Medicine
|
January 21, 2006
Response to "Interactions between pharmaceutical representatives and doctors in training: a thematic review"
Leana S Wen, Christopher McCoy
Clinical Therapeutics
|
May 17, 2003
Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis
Christopher McCoy, Samuel James Matthews
Clinical Therapeutics
|
May 17, 2003
Thalidomide: a review of approved and investigational uses
S James Matthews, Christopher McCoy
Clinical Practice and Cases in Emergency Medicine
|
May 22, 2025
Pyoderma Grangrenosum
Reza Aghaei, Edmund Hsu, Christopher McCoy
Pharmacotherapy
|
October 28, 2009
Clinically significant adverse events from a drug interaction between quetiapine and atazanavir-ritonavir in two patients
Todd M Pollack, Christopher McCoy, Wendy Stead
Journal of Education & Teaching in Emergency Medicine
|
July 19, 2023
A Case Report of May-Thurner Syndrome Identified on Abdominal Ultrasound
Michelle Brown, Edmund Hsu, Christopher McCoy, et al.
American Journal of Medical Quality : the Official Journal of the American College of Medical Quality
|
May 23, 2015
Delayed awareness of clinically significant test results on hospital services without an automated alert system
Ruth Bates, Andrew Rosenbaum, Christopher McCoy, et al.
Page
of 4